메뉴 건너뛰기




Volumn 9, Issue 8, 2014, Pages 1638-1654

The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3- hydroxyphenyl)piperidine class of pure opioid receptor antagonists

Author keywords

alvimopan; drug design; JDTic; medicinal chemistry; opioid antagonists

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALVIMOPAN; KAPPA OPIATE RECEPTOR ANTAGONIST; LY 255582; NALTREXONE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG; NARCOTIC ANTAGONIST; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; PROTEIN BINDING;

EID: 84905259899     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201402142     Document Type: Review
Times cited : (19)

References (54)
  • 20
    • 84905221353 scopus 로고    scopus 로고
    • Cubist Announces FDA Approval for Expanded Use of ENTEREG (accessed March 28, 2014)
    • Cubist Announces FDA Approval for Expanded Use of ENTEREG, www.cubist.com/news/110-cubist-announces-fda-approval-for- expanded-use-of- entereg-r (accessed March 28, 2014).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.